How MSI and TMB Factor into Current Biomarker Testing PanelsVideo Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Alexander Bastian speaks about the need for a sustainable model of pricing as related to cancer treatments and drug development. He talks about indication-based pricing or tumor-based pricing—says that is compelling, but not necessarily possible in the US.
Dr. Mesa recognizes that although genotypic data is not yet being used to select treatment choice or dosing in myelofibrosis, it is used to address the issues of prognosis and burden of disease.